Industry news

Horizon Pharma plc to acquire DepoMed Inc. for $3 billion

Read time: 1 mins

Last updated:8th Jul 2015

Published:8th Jul 2015

Source: Pharmawand

Horizon Pharma plc announced a proposal to acquire all outstanding shares of Depomed, Inc. for approximately $3.0 billion. DepoMed products in the USA include Nucynta ER for pain control, Cambria for migraine, PecFent for cancer pain and the company holds world rights for Gralise and Zipsor for pain control as well as non-North American rights for Glumetza for diabetes. This is a contested bid.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Eyenovia Inc.,to accelerate development of MicroPine and explore alternatives to maximize shareholder value.

Eyenovia, Inc. announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to explore strategic alternatives to maximize shareholder value

1 mins

Industry news

GenMab A/S to acquire ProfoundBio and with it Rina-S, an FRalpha ADC, to treat ovarian cancer

Genmab A/S and ProfoundBio, Inc. announce that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction.

1 min

Industry news

Acorda Therapeutics files for voluntary bankruptcy

Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to Inbrija, Ampyra, and Fampyra for $185 million.

1 min

See all news